MEVASTATIN


Synonyms	Mevastatin
UNII	1UQM1K0W9X
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AJLFOPYRIVGYMJ-INTXDZFKSA-N
Smiles	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
InChI	InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H34O5
Molecular Weight	390.51
AlogP	3.97
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	7.0
Polar Surface Area	72.83
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	28.0

Assay Description	Organism	Bioactivity
Increase of poly-3-hydroxybutyrate production in rCAB8 transgenic Nicotiana tabacum (tobacco) plastids at 0.1 to 10 uM sprayed on five-leaf stage plant once in a week measured after 2 weeks relative to control	Nicotiana tabacum	None
Increase of poly-3-hydroxybutyrate production in BC3 transgenic Nicotiana tabacum (tobacco) plastids at 10 uM sprayed on five-leaf stage plant once in a week measured after 2 weeks relative to control	Nicotiana tabacum	None
Increase of poly-3-hydroxybutyrate production in BC3 transgenic Nicotiana tabacum (tobacco) plastids at 1 uM sprayed on five-leaf stage plant once in a week measured after 2 weeks relative to control	Nicotiana tabacum	192.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL54440
FDA SRS	1UQM1K0W9X
PubChem	64715
SureChEMBL	SCHEMBL1116
ZINC	ZINC03833876

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).